WHO Sounds Alert Over Severe Lack of Obesity Injections

Less than 10% of people who could benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its initial recommendations on the drugs.

Given over a billion individuals worldwide now classified as obese, it is calling for broader and more equitable access to GLP-1 medication.

According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to widespread availability to the jabs that can help people shift substantial weight, says the agency.

GLP-1 Therapy Scarcity

Even under the present most favorable outlook, the supply of such drugs might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization.

The guideline urges nations and manufacturers to widen availability, through strategies such as patent sharing.

Exclusive production rights on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.

How Obesity Jabs Function

GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and boost feelings of fullness so users reduce food intake.

People typically see weight reduction within a few weeks of commencing the weekly injections.

Studies suggests users may put most of the weight back on a year later of stopping the medication, as their usual hunger come back.

To be carrying excess weight increases your chance for developing diseases, like diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity impacts people in all nations and was associated with millions of deaths worldwide in 2024, according to the health agency.